Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 職業醫學與工業衛生研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46265
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor黃耀輝
dc.contributor.authorYu-An Laien
dc.contributor.author賴昱安zh_TW
dc.date.accessioned2021-06-15T05:00:43Z-
dc.date.available2015-09-13
dc.date.copyright2010-09-13
dc.date.issued2010
dc.date.submitted2010-07-28
dc.identifier.citation1. Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, Waalkes M. Health Effects, Mechanisms of Actions, and Research Issues. Environ Health Perspect 1999;107: 593-597.
2. Abernathy CO, Thomas DJ, Calderon RL. Health Effects and Risk Assessment of Arsenic. J Nutr 2003; 133:1536S-1538S.
3. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, Gamble MV, Graziano JH. Arsenic Metabolism, Genetic Susceptibility, and Risk of Premalignant Skin Lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 2007; 16: 1270-1278.
4. AJCC, 1997. Cancer Staging Manual Fifth Edition.
5. Amling CL. The Association between Obesity and the Progression of Prostate and Renal Cell Carcinoma. Urol Oncol 2004; 22: 478-484.
6. Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML. A Review of The Enzymology of Arsenic Metabolism and A New Potential Role of Hydrogen Peroxide in the Detoxication of the Trivalent Arsenic Species. Toxicol Appl Pharmacol 2004; 198: 327-335.
7. ATSDR, 2010. Agency for Toxic Substances and Disease Registry, Toxicological Profile for Vanadium.
8. Baker J, Reilly P, Moore M, Williams D. Cadmium Levels in the Lung, Liver, Kidney Cortex, and Urine Samples from Australians without Occupational Exposure to Metals. Arch Environ Health 2002; 57: 69-77.
9. Batariova A, , Spevackova V, Benes B et al. Blood and Urine Levels of Pb, Cd and Hg in the General Population of the Czech Republic and Proposed Reference Values. Int J Hyg Environ Health 2006; 209: 359-366.
10. Baumler J, Obersteg JI, Shafer R. Determination of the Level of Arsenic in Human Bodies. Dtsch Z Gesamte Gerichtl Med 1968; 64: 56-61.
11. Beaumont JJ, Sedman RM, Reynolds SD, Sherman CD, Li LH, Howd RA, Sandy MS, Zeise L, Alexeeff GV. Cancer Mortality in a Chinese Population Exposed to Hexavalent Chromium in Drinking Water. Epidemiology 2008; 19: 12-23.
12. Benedetti JL, Samuel O, Dewailly E, Gingras S, Lefebvre MA. Levels of Cadmiun in Kidney and Liver Tissues among a Canadian Population(Province of Quebec). J Toxicol Environ Health A 2010; 56: 145-163.
13. Bernard A. Cadmium & its Adverse Effects on Human Health. Indian J Med Res 2008; 128: 557-564.
14. Braman RS, Foreback CC. Methylated Forms of Arsenic in the Environment. Science 1973; 182: 1247-1249.
15. Buchet JP, Lauwerys R, Roels H. Comparison of the Urinary Excretion of Arsenic Metabolites After a Single Oral Dose of Sodium Arsenite, Monomethylarsonate, or Dimethylarsinate in Man.Int. Arch Occup Environ Health 1981; 48: 71-79.
16. Calvo FB, Junior DS, Rodrigues CJ, Krug FJ, Marumo JT, Schor N, Bellini MH. Variation in the Distribution of Trace Elements in Renal Cell Carcinoma. Biol Trace Elem Res 2009.
17. Chai CY, Huang YC, Hung WC, Kang WY, Chen WT. Arsenic Salt-Induced DNA Damage and Expression of Mutant p53 and COX-2 Proteins in SV-40 Immortalized Human Uroepithelial Cells. Mutagenesis 2007; 22:403-408.
18. Chashschin VP, Artunina GP, Norseth T. Congenital Defects, Abortion and Other Health Effects in Nickel Refinery Workers. Sci Total Environ 1994; 148: 287-291.
19. Chen CJ, Wang CJ. Ecological Correlation between Arsenic Level in Well Water and Age-adjusted Mortality from Malignant Neoplasms. Cancer Res 1990; 50: 5470-5474.
20. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A Retrospective Study on Malignant Neoplasms of Bladder, Lung and Liver in Blackfoot Disease Endemic Area in Taiwan. Br J Cancer1986; 53: 399-405.
21. Chen CJ, Kuo TL, Wu MM. Arsenic and Cancers. Lancet 1988; 1: 414-415.
22. Chen R, Wei L, Huang H. Mortality From Lung Cancer among Copper Miners. Br J Ind Med 1993; 50: 505-509.
23. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ. Incidence of Transitional Cell Carcinoma and Asenic in Drinking Water A Follow-up Study of 8,102 Residents in an Arseniasis-endemic Area in Northeastern Taiwan. Am J Epidemiol 2001; 153: 411-418.
24. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH et al. Arsenic Methylation Capacity, Body retention, and Null Genotypes of Glutathione S-Transferase M1 and T1 among Current Arsenic-Exposed Residents in Taiwan. Mutat Res 1997; 386: 197-207.
25. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising Incidence of Renal Cell Cancer in the United States. JAMA 1997; 281: 1628-1631.
26. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, Mazumder DN, Hernandez AL, Smith AH. Family Correlations of Arsenic Methylation Patterns in Children and Parents Exposed to High Concentrations of Arsenic in Drinking Water. Environ Health Perspect 2002; 110: 729-733.
27. Cherian MG , Howell SB, Imura N, Klaassen CD, Koropatnick J, Lazo JS, Waalkes MP. Role of Metallothionein in Carcinogenesis. Toxicol Appl Pharmacol 1994; 126:1-5.
28. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of Selenium Supplementation for Cancer Prevention in Patients with Carcinoma of the Skin. JAMA 1999; 276: 1957-1963.
29. Clewell HJ, Thomas RS, Gentry PR, Crump KS, Kenyon EM, El-Masri HA, Yager JW. Research Toward the Development of a Biologically Based Dose Response Assessment for Inorganic Arsenic Carcinogenicity: A progress Report. Toxicol Appl Pharmacol 2007; 222: 388-398.
30. Cocco P, Hua F, Boffetta P, Carta P, Flore C, Flore V, Onnis A, Picchiri GF, Colin D. Mortality of Italian Lead Smelter Workers. Scand J Work Environ Health 1997; 23: 15-23.
31. Crump C, Crump K, Hack E, Luippold R, Mundt K, Liebig E, Panko J, Paustenbach D, Proctor D. Dose-Response and Risk-Assessment of Airborne Hexavalent Chromium and Lung Cancer Mortality. Risk Anal 2003; 23: 1147-1163.
32. Csanaky I, Nemeti B, Gregus Z. Dose-Dependent Biotransformation of Arsenite in Rats-Not S-Adenosylmethionine Depletion Impairs Arsenic Methylation at High Dose. Toxicology 2003; 183: 77-91.
33. Del Razo LM, Garcia-Vargas GG., Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrián ME. Altered profile of Urinary Arsenic Metabolites in Adults with Chronic Arsenicism. Arch Toxicol 1997; 71: 211-217.
34. Deng DX, Chakrabarti S, Waalkes MP ,Cherian MG. Metallothionein and Apoptosis in Primary Human Hepatocellular Carcinoma and Metastatic Adenocarcinoma. Histopathology 1998; 32: 340-347.
35. Długaszek M, Kaszczuk M, Mularczyk-Oliwa M. Magnesium, Calcium, and Trace Elements Excretion in 24-h Urine. Biol Trace Elem Res 2010.
36. Dobrowolski Z, Drewniak T, Kwiatek W, Jakubik P. Trace Elements Distribution in Renal Cell Carcinoma Depending on Stage of Disease. Eur Urol 2002; 42: 475-480.
37. Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, Parvez F, Levy D, Factor-Litvak P, Graziano JH. Folate, Homocysteine, and Arsenic Metabolism in Arsenic-Exposed Individuals in Bangladesh. Environ Health Perspect 2005; 113: 1683-1688.
38. Gibb HJ, Lees PSJ, Pinsky PF, Rooney BC. Lung Cancer among Workers in Chromium Chemical Production. Am J Ind Med 2000; 38: 115-126.
39. Goering PL, Klaassen CD. Tolerance to Cadmium-Induced Hepatotoxicity Following Cadmium Pretreatment. Toxicol Appl Pharmacol 1984; 74:308-313.
40. Goulle JP, Mahieu L, Castermant J, Neveu N, Bonneau L, Lainé G, Bouige D, Lacroix C. Metal and Metalloid Multi-Elementary ICP-MS Validation in Whole blood, Plasma, Urine and Hair Reference Values. Forensic Sci Int 2005; 153: 39-44.
41. Grimsrud TK, Peto J. Persisting Risk of Nickel Related Lung Cancer and Nasal Cancer among Clydach Refiners. Occup Environ Med 2006; 63: 365-366.
42. Guo HR, Chiang HS, Hu H, Stuart R. Lipsitz, Richard R. Monson. Arsenic in Drinking Water and Incidence of Urinary Cancers. Epidemiology 1997; 8: 545-550.
43. Hamadeh HK., Vargas M, Lee E, Menzel DB. Arsenic Disrupts Cellular Levels of p53 and mdm2:A Potential Mechanism of Carcinogenesis. Biochem Biophys Res Commun 1999; 263: 446-449.
44. Heitland P, Koster HD. Biomonitoring of 30 Trace Elements in Urine of Children and Adults by ICP-MS. Clin Chim Acta 2006; 365: 310-318.
45. Hellström L, Elinder CG, Dahlberg B, Lundberg M, Järup L, Persson B, Axelson O. Cadmium Exposure and End-Stage Renal Disease. Am J Kidney Dis 2001; 38: 1001-8.
46. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraimb A. The Accumulation and Toxicity of Methylated Arsenicals in Endothelial Cells: Important Roles of Thiol Compounds. Toxicol Appl Pharmacol 2004; 198: 458-467.
47. Hong F, Jin T, Zhang A. Risk Assessment on Renal Dysfunction Caused by Co-Exposure to Arsenic and Cadmium Using Benchmark Dose Calculation in a Chinese Population. BioMetals 2004; 17: 573-580.
48. Hobbesland A, Kjuus H, Thelle DS. Mortality from Cardiovascular Diseases and Sudden Death in Ferroalloy Plants. Scand J Work Environ Health 1997; 23: 334-341.
49. Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and Kidney Cancer Mortality Associated with Arsenic in Drinking water in Cordoba, Argentina. Int J Epidemiol 1998; 27: 561-569.
50. Hsieh YF, Ling GC, Lu YB. Incidence of Tumor of the Renal Pelvis in Taiwan. J Formos Med Assoc 1979; 78: 749-753.
51. Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, Lue LC, Chen CJ. Urinary Levels of Inorganic and Organic Arsenic Metabolites among Residents in an Arseniasis-Hyperendemic Area in Taiwan. J Toxicol Environ Health 1998; 54: 431-444.
52. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL, Yang MH, Chen CJ. Determinants of Inorganic Arsenic Methylation Capability among Residents of the Lanyang Basin, Taiwan: Arsenic and Selenium Exposure and Alcohol Consumption. Toxicol Lett 2003; 137: 49-63.
53. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. Arsenic Methylation Capability and Hypertension Risk in Subjects Living in Arseniasis-Hyperendemic Areas in Southwestern Taiwan. Toxicol Appl Pharmacol 2007; 218: 135-142.
54. IARC. Arsenic and Arsenic Compounds. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans; Suppl 7. Overall Evaluations of Carcinogenicity: Updating of IARC Monographs Volumes 1-42. Lyon: France, World Health Organization, International Agency for Research on Cancer, 1987; 29-33.
55. Jiang Y, Lu J, Mai H. Effects of Manganese Exposure on ECG and blood Pressure. Ind Health Occup Dis 1996; 22: 341-343.
56. Kagi JH. Overview of Metallothionein. Methods Enzymol 1991; 205: 613-626.
57. Kusial RA, Springer J, Ritchie AC, Muller J. Carcinoma of the Lung in Ontario Gold Miners: Possible Aetiological Factors. Br J Ind Med 1991; 48: 808-817.
58. Lalor GC. Review of Cadmium Transfers From Soil to Humans and its Health Effects in the Jamaican Environment. Sci Total Environ 2008; 400: 162-172.
59. Lemos VA, Carvalho AL. Determination of Cadmium and Lead in Human Biological Samples by Spectrometric Techniques: A Review. Environ Monit Assess 2009.
60. Lightfoot N, Berriault C, Semenciw R. Mortality and Cancer Incidence in a Nickel Cohort. Occup Med 2010; 60: 211-218.
61. Lin SM, Chiang CF, Yang MH. Arsenic Concentration in the Urine of Patients with Blackfoot Disease and Bowen’s Disease. Biol Trace Elem Res 1985; 8: 11-18.
62. Lipworth L, Tarone RE, McLaughlin JK. The Epidemiology of Renal Cell Carcinoma. J Urol 2006; 176: 2353-2358.
63. Maitani T, Saito N, Abe M, Uchiyama S , Saito Y. Chemical Form-Dependent Induction of Hepatic Zinc Thionein by Arsenic Administration and Effect of Co-Administered Selenium in Mice. Toxicol Lett 1987; 39: 63-70.
64. Marumo K, Satomi Y, Miyao N, Hasegawa M, Tomita Y, Igarashi T, Onishi T, Nakazawa H, Fukuda M, Ozono S, Terachi T, Tsushima T, Nakamoto T, Kawamura J. The Prevalence of Renal Cell Carcinoma: A Nation-Wide Survey in Japan in 1997. Int J Urol 2001; 8: 359-365.
65. Marumo K, Kanayama H, Miyao N, Nakazawa H, Ozono S, Horie S, Nagamori S, Igarashi T, Hasegawa M, Kimura G, Nakao M, Nakamoto T, Naito S. Prevalence of Renal Cell Carcinoma: A Nation-Wide Survey in Japan, 2002. Int J Urol 2007; 14: 479-482.
66. Maret W. Oxidative Metal Release from Metallothionein via Zinc-Thiol/Disulfide Interchange. Proc Natl Acad Sci 1994; 91:237-241.
67. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in Drinking Water and Cerebrovascular Disease, Diabetes Mellitus, and Kidney Disease in Michigan: a Standardized Mortality Ratio Analysis. Environ Health 2007; 6: 4.
68. Menke A, Muntner P, Silbergeld EK, Platz EA, Guallar E. Cadmium Levels in Urine and Mortality among U.S. Adults. Environ Health Perspect 2009; 117: 190-196.
69. Meplan C, Richard MJ, Hainaut P. Metalloregulation of the Tumor Suppressor Protein p53: Zinc Mediates the Renaturation of p53 After Exposure to Metal Chelators in Vitro and in Intact Cells. Oncogene 2000; 19: 5227-5236.
70. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of Action of Arsenic Trioxide. Cancer Res 2002; 62: 3893-3903
71. Nordberg GF, Jina TT, Hong F, Zhang A, Buchet JP, Bernard A. Biomarkers of Cadmium and Arsenic Interactions. Toxicol Appl Pharmacol 2005; 206: 191-197.
72. Nogawa K, Honda R, Kido T, Tsuritani I, Yamada Y, Ishizaki M, Yamaya H. A Dose-Response Analysis of Cadmium in the General Environment with Special Reference to Total Cadmium Intake Limit. Environ Res 1989; 48: 7-16.
73. Orlowski C, Piotrowski JK, Subdys JK, Gross A. Urinary Cadmium as Indicator of Renal Cadmium in Humans: an Autopsy Study. Hum Exp Toxicol 1998; 17: 302-306.
74. Özgür S, Sümner H, Kocoglu G. Rickets and Soil Strontium. Arch Dis Child 1996; 75: 524-526.
75. Rahman M, Wingren G, Axelson O. Diabetes Mellitus among Swedish Art Glass Workers: an Effect of Arsenic Exposure? Scand J Work Environ Health 1996; 22: 146-149.
76. Rahil-Khazen R, Bolann BJ, Myking A, Ulvik RJ. Multi-Element Analysis of Trace Element Levels in Human Autopsy Tissues by Using Inductively Coupled Atomic Emission Spectrometry Technique (ICP-AES). J Trace Elem Med Biol 2002; 16:15-25.
77. Samanta G, Chowdhury UK, Mandal BK, Chakraborti D, Sekaran NC, Tokunaga H, Ando M. High Performance Liquid Chromatography Inductively Coupled Plasma Mass Spectrometry for Speciation of Arsenic Compounds in Urine. Microchem J 2000; 65: 113-127.
78. Saric M, Hrustic O. Exposure to Airborne Manganese and Arterial Blood Pressure. Environ Res 1975; 10: 314-318.
79. Sato M, Bremner I. Oxygen Free Radicals and Metallothionein. Free Radic Biol Med 1993; 14: 325-337.
80. Schrauzer GN .Interactive Effects of Selenium and Cadmium on Mammary Tumor Development and Growth in MMTV-Infected Female Mice. A Model Study on the Roles of Cadmium and Selenium in Human Breast Cancer. Biol Trace Elem Res 2008; 123: 27-34.
81. Schrauzer GN. Effects of Selenium and Low Levels of Lead on Mammary Tumor Development and Growth in MMTV-Infected Female Mice. Biol Trace Elem Res 2008; 125: 268-275.
82. Selevan SG, Landrigan PJ, Stern FB, Jones JH. Mortality of Lead Smelter Workers. Am J Epidemiol 1996; 122: 673-683.
83. Shamberger RJ, Tytko SA, Willis CE. Antioxidants and Cancer: Part VI. Selenium and Age-Adjusted Human Cancer Mortality. Arch Environ Health 1976; 31:231-235.
84. Shibata A, Ohneseit PF, Tsai YC, Spruck CH, Nichols PW, Chiang HS, Lai MK, Jones PA. Mutational Spectrum in the p53 Gene in Bladder Tumors from the Endemic Area of Black foot Disease in Taiwan. Carcinogenesis 1994; 15: 1085-1087.
85. Stafford H, Saltzatein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/Ethnic and Gender Disparities in Renal Cell Carcinoma Incidence and Survival. J Urol 2008; 179: 1704-1708.
86. Steenland K, Selevan S, Landrigan P. The Mortality of Lead Smelter Workers: an Update. Am J Public Health 1992; 82: 1641-4.
87. Sun G, Xu Y, Li X, Jin Y, Li B, Sun X. Urinary Arsenic Metabolites in Children and Adults Exposed to Arsenic in Drinking Water in Inner Mongolia, China. Environ Health Perspect 2007; 115: 648-652.
88. Tapio S, Grosche B. Arsenic in the Aetiology of Cancer. Mutat Res 2006; 612: 215-246
89. Thomas DJ, Waters SB, Styblo M. Elucidating the Pathway for Arsenic Methylation. Toxicol Appl Pharmacol 2004; 198: 319-326.
90. Tice RR, Yager JW, Andrews P, Crecelius E. Effect of hepatic methyl donor status on urinary excretion and DNA damage in B6C3F1 mice treated with sodium arsenite. Mutat Res 1997; 86: 315–334.
91. Tomasek L, Darby SC. Recent Results from the Study of West Bohemian Uranium Miners Exposed to Radon and Its Progeny. Environ Health Perspect 1995; 103: 55-57.
92. Tsai SM, Wang TN, Ko YC. Mortality for Certain Disease in Areas with High Levels of Arsenic in Drinking Water. Arch Environ Health 1999; 54: 186-193.
93. Tseng CH, Huang YK, Huang YL. Arsenic Exposure, Urinary Arsenic Speciation, and Peripheral Vascular Disease in Blackfoot Disease-Hyperendemic Villages in Taiwan. Toxicol Appl Pharmacol 2005; 206: 299-308.
94. Vahter M. Mechanisms of Arsenic Biotransformation. Toxicology 2003; 181-182: 211-217.
95. Vather M. Methylation of Inorganic Arsenic in Different Mammalian Species and Population Groups. Sci Prog 1999; 82: 69-88.
96. Vahter M. Environmental and Occupational Exposure to Inorganic Arsenic. Acta Pharmacol Toxicol. 1986; 59: 31-34.
97. Viren JR, Silvers A. Unit Risk Estimates for Airborne Arsenic Exposure: an Updated View Based on Recent Data from Two Copper Smelter Cohorts. Regul Toxicol Pharmacol 1994; 20: 125-138.
98. Wilson RT, Donahue M, Gridley G, Adami J, Ghormli L, Dosemeci M.Shared Occupational Risks for Transitional Cell Cancer of the Bladder and Renal Pelvis among Men and Women in Sweden. Am J Ind Med 2008; 51: 83-99.
99. Wu MM, Kuo TL, Hwang YH, Chen JC. Dose-Response Relation between Arsenic Concentration in Well Water and Mortality from Cancers and Vascular Disease. Am J Epidemiol 1989; 130: 1123-1113.
100. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. A Hot Spot for p53 Mutation in Transitional Cell Carcinoma of the Bladder Clues to the Etiology of Bladder Cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 611-616.
101. Yaman M, Kaya G, Yekeler H. Distribution of Trace Metal Concentrations in Paired Cancerous and Non-Cancerous Human Stomach Tissues. World J Gastroenterol 2007; 13: 612-618.
102. Yaman M, Kaya G, Simsek M. Comparison of Trace Element Concentrations in Cancerous and Noncancerous Human Endometrial and Ovary Tissues. Int J Gynecol Cancer 2007; 17:220-228.
103. Yang CY, Chiu HF, Wu TN. Chuang HY, Ho SC. Reduction in Kidney Cancer Mortality Following Installation of a Tap Water Supply System in an Arsenic-Endemic Area of Taiwan. Arch Environ Health 2004; 59: 484-488.
104. Yoshida T, Yamauchi H, Sun GF. Chronic Health Effects in People Exposed to Arsenic via the Drinking Water:Dose–Response Relationships in Review. Toxicol Appl Pharmacol 2004; 198: 243-252.
105. Yoshinaga J, Suzuki T. Sex- and Age-Related Variation in Element Concentrations of Contemporary Japanese Ribs. Sci Total Environ 1989; 79: 209-221.
106. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of Prediagnostic Selenium Level in Toenails and the Risk of Advanced Prostate Cancer. J Natl Cancer 1998; 90: 1219-1224.
107. Yu RC, Hsu KH, Chen CJ, John R. Froines. Arsenic Methylation Capacity and Skin Cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1259-1262.
108. Zaichick S, Zaichick V. The Effect of Age and Gender on 37 Chemical Element Contents in Scalp Hair of Healthy Humans. Biol Trace Elem Res 2010; 134: 41-54.
109. Zaichick V, Zaichick S, Karandashev V, Nosenko S. The Effect of Age and Gender on Al, B, Ba, Ca, Cu, Fe, K, Li, Mg, Mn, Na, P, S, Sr, V, and Zn Contents in Rib Bone of Healthy Humans. Biol Trace Elem Res 2009; 129: 107-115.
110. 王明光:實用儀器分析。台北:合記書局,2003。
111. 林敬二譯,司寇克著:儀器分析。第五版。台北:亞美書版,1999。
112. 林和靜,2001。利用Microbore-HPLC-ICP-MS連線分析系統進行尿中硒物種的分析研究。[碩士論文]國立清華大學原子科學研究所。
113. 林桂安,2005。細胞鹼化對金屬硫蛋白基因誘導之機制研究。[博士論文]國立清華大學生命科學研究所。
114. 吳宗穎:腎臟系統簡易學。台北:合記書局,2005。
115. 衛生署,2008。死因統計。Accessed on July, 2009 at http ://www.doh.gov.tw/
116. 衛生署,2008。台灣國民營養健康狀況變遷調查。Accessed on December, 2009 at http :// food.doh.gov.tw/FOODNEW/research/NationalResearch.aspx
117. 陳由瑄,2003。食用牡蠣後尿中砷代謝物分布之變異性。[碩士論文]國立台灣大學職業醫學與工業衛生研究所。
118. 陳健文,2006。以病例對照研究法探討成藥對腎功能影響。[碩士論文]國立台灣大學預防醫學研究所。
119. 施惟量,2001。砷暴露者與抽菸者移行上皮細胞癌之p53基因突變譜之比較研究。[碩士論文]國立台灣大學流行病學研究所。
120. 江博暉、江博煌、吳文正、康智雄:尿路上皮癌新知。高雄:人生書局,2006。
121. 賴敏裕:臨床腎臟病學-檢查、診斷、疾病各論。台北:合記書局,2005。
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46265-
dc.description.abstract流行病學研究中已經證實砷的暴露與移行性上皮癌之間有著顯著的劑量反應關係存在,但目前仍然相當缺乏重金屬與砷物種型態在泌尿道癌症病患生物檢體中之分布資料。因此,本次研究為探討多元素金屬在泌尿道癌症病患腎皮質、腎盂、輸尿管與尿液中之分布情形,以及了解泌尿道癌症病患體內甲基化代謝能力之情形。
在本次研究中,一共招募了17名來自於台大醫院泌尿部的移行性上皮癌與腎皮質癌個案,並依照TNM的癌症分類系統進行癌症病程的分級。同時並以問卷收集個案之年齡、身高、體重、運動習慣、抽菸、酗酒、飲茶、咖啡攝取、職業暴露史、飲食習慣、中草藥使用與家族及病史等資料。
在檢體的收樣上,以離心管收集個案手術當天早晨之第一泡尿液,並由醫師協助於腎臟摘除後進行組織檢體收集。正常與腫瘤組織樣本先經密閉式微波消化系統進行前處理,再以感應耦合電漿質譜儀進行砷、鎘、硒、錳與鍶等金屬之分析。同時並同步分析NIST 1577C牛肝標準參考品,用於分析方法之品質管制。尿液樣本則會先經過0.45 μm的濾膜過濾,其濾液以ICP-MS分析尿中之砷、鎘、硒、釩、鉻、錳、鎳、銅、鉛與鍶之濃度。尿液中砷物種的測定則是先以高效率液相層析儀層析出三價砷、雙甲基砷酸、單甲基砷酸與五價砷,其層析液再直接串聯至感應耦合電漿質譜儀定量。尿液分析的部分,以Seronorm尿液標準參考品之同步分析作為分析之品質管制步驟。
在本次研究結果中,可以看出隨著泌尿道癌症病患尿液中硒濃度的增加,尿液中的總砷與雙甲基砷酸也有顯著上升的趨勢(p<0.05),另外,資料中也顯示出女性比起男性有較好的甲基化能力,但隨著年齡較增長之個案其甲基化能力則有降低的趨勢。而不同的金屬在各個癌症分期中,其濃度分布趨勢則各有不同。
在組織金屬濃度的分析上,砷與鎘在腎皮質正常組織中的濃度都比腎盂與輸尿管正常組織中高(p<0.05),而鎘在正常組織中則是有比腫瘤組織還要高的情形(p<0.05),砷在腫瘤與正常組織中則未看出差異。
本前驅研究的初步結果顯示,不同金屬在體內之累積,可能與體內砷物種型態之表現有相關。而各種金屬在不同組織器官上,確實也存在有濃度分布的差異。在後續的研究上,應進一步探討不同金屬元素與泌尿道癌症之間的交互作用,及其與癌症病程、年齡及性別對於體內甲基化能力的影響。針對不同部位之正常組織及腫瘤組織中金屬元素之分布,也需進一步比較,並確認在本研究中所看到的趨勢變化。
zh_TW
dc.description.abstractBackground
Epidemiological studies have demonstrated a significant dose-response relationship between arsenic exposure and the cancers of the urinary organs, especially transitional cell carcinoma (TCC). However, there was still lack of concentrations data of metal and arsenic species in the biological samples of urinary cancer subjects. Hence, the goals of this study were set: (1) to explore the relationship of renal cell carcinoma and transitional cell carcinoma, respectively, with the distributions of metal levels in renal cortex, pelvis and ureter, and (2) to study the association of the occurrence of renal cell carcinoma and transitional cell carcinoma, respectively, with the metabolic methylation in human body.
Material and Methods
Study subjects
In this study, 17 urinary cancer subjects were recruited from the Urological Department of the National Taiwan University Hospital, with TCC or RCC at different stages. All subjects were histologically diagnosed, and categorized into different tumors stages based on the 1997 TNM classification system.
Questionnaire
Questionnaire was applied to collect study subject’s personal information on risk factors of urinary cancer, such as age, body height, weight, exercise habits, smoking history, occupational exposure history, alcohol drinking, tea consumption, coffee consumption, dietary habit, use of herbal medicine and family disease history.
Collection and preparation of samples
We use the 50 ml centrifuge tube to collect the morning void urine from subject, and through the assistant of surgen to obtain the tissue samples after surgery.Tissue samples were decomposed in closed vessels using a microwave-assisted method. Inductively coupled plasma mass spectrometry was used to analyze the contents of As, Cd, Se, Mn and Sr in normal and tumor kidney tissue. The accuracy of the ICP-MS (7500C, Agilent Technologies, Japan) analysis was validated with NIST SRM 1577c bovine liver. Urine sample was filtered through a 0.45-μm membrane prior to being subjected to ICP-MS and HPLC-ICPMS analysis. Trace metals including As, Cd, Se, V, Cr, Mn, Ni, Cu, Pb and Sr in urine were determined with ICP-MS, while As3+, DMA, MMA and As5+ were determined by HPLC-ICP-MS. Accuracy was checked with the SERO trace elements reference in urine.
Results & Discussions
Urinary concentration of total arsenic and the DMA percentage in total arsenic concentration significantly increased as the concentration of urinary selenium increased. Besides, results of the present study suggested that women presented greater capability in arsenic methylation than men, and the methylation capability diminished as the age increasing. This study also presented differences in the concentrations distributions of the selected trace metals in urine at different cancer stages. These findings indicated that some trace metals might play important roles in the pathogenesis of urinary cancer. Moreover, the concentrations of As and Cd in normal cortex were higher than in normal pelvis and normal urinary track (p<0.05). The Cd concentration in normal tissue was found to be higher than those in tumor tissue, whereas As levels in tumor tissue was not found to be different than those in normal tissue.
Conclusions, the metal accumulation in human body might affect the concentration distribution of arsenic species. Furthermore, there were different metal concentration distributions in different human urinary organs. Futher research should study the interaction between the trends of different metals and urinary cancer, moreover, to realize the association among metals, cancer stage, age, gender, and methylation capability. Besides, it needs to explore the metal distributions in normal and tumor tissues. It is also warranted to involve more participants to obtain statistically significant data in order to confirm the metal distribution.
en
dc.description.provenanceMade available in DSpace on 2021-06-15T05:00:43Z (GMT). No. of bitstreams: 1
ntu-99-R97841004-1.pdf: 996661 bytes, checksum: 9947e2911a54d86a2b8a9dbd88eb6234 (MD5)
Previous issue date: 2010
en
dc.description.tableofcontents第一章 前言 6
1.1研究背景 6
第二章 文獻探討 7
2.1泌尿道相關癌症研究 7
2.1.1腎細胞癌(renal cell carcinoma, RCC) 7
2.1.2移行性上皮細胞癌(transitional cell carcinoma, TCC) 8
2.2砷與泌尿道癌症 9
2.2.1砷之環境分布與體內之代謝 9
2.2.2與砷暴露有關之泌尿道癌症的流行病學研究 10
2.3其他與泌尿道癌症有關之金屬暴露研究 11
2.4其他金屬暴露對人之影響 12
2.5泌尿道癌症有關之致癌機轉 14
2.6微量金屬分析方法 15
2.6.1 ICP-MS介紹 15
2.6.2 HPLC-ICP-MS介紹 17
2.7研究目的 18
第三章 材料與方法 19
3.1研究對象 19
3.2問卷設計 19
3.3泌尿道癌症分類系統(TNM) 20
3.4生物檢體樣本收集及處理 20
3.4.1尿液樣本收集 20
3.4.2組織樣本收集 20
3.4.3尿液樣本測定與前處理 21
3.4.4組織樣本測定與前處理 21
3.4.5尿液多元素分析檢量線配製 21
3.4.6尿液砷物種分析檢量線配製 21
3.4.7組織多元素分析檢量線配製 21
3.5儀器設備 22
3.6試藥與試劑 22
3.7試劑配製 23
3.8分析分方法之品質控制 23
3.8.1偵測極限 23
3.8.2添加標準品分析 23
3.8.3標準參考樣本分析 23
3.9統計分析 24
第四章 結果 25
4.1受試者基本資料 25
4.2尿液中多元素金屬之分布情形 25
4.2.1尿液中多元素金屬分布與癌症病程之關係 25
4.2.2不同性別、年齡層與不同腫瘤部位病患之尿液金屬濃度分布 26
4.3尿液中砷物種與其甲基化指標之分布情形 26
4.3.1尿液中砷物種與一、二級甲基化指標在不同癌症病程之分布 26
4.3.2不同性別、年齡層與腫瘤發生部位個案尿液中砷物種與一、二級甲基化指標之分布 27
4.4尿液中各金屬與砷物種之相關性 27
4.5正常與腫瘤組織中金屬元素分佈 28
第五章 討論 29
5.1砷與泌尿道上皮癌之關係與其在尿液中之分布 29
5.2多元素金屬在泌尿道上皮癌尿液中之分布 29
5.3砷物種在泌尿道上皮癌尿液中之分布 33
5.4多元素在泌尿道上皮癌個案組織中累積之情形 34
5.5本研究之限制 36
第六章 結論 37
第七章 參考文獻 38

表目錄
表 1 ICP-MS元素分析之同位素干擾來源 48
表 2 ICP-MS進行尿液樣本及組織樣本分析之參數設定 49
表 3 HPLC-ICP-MS進行尿液砷物種分析之參數設定 50
表 4 Microwave進行組織樣本消化之參數設定51
表 5 尿液中多種金屬元素分析檢量線配製 52
表 6 砷物種分析檢量線配製 53
表 7 組織樣本多種金屬元素分析檢量線配製 54
表 8 尿液中各金屬元素標準溶液檢量線之R2值與方法偵測極限值 55
表 9 組織樣本中各金屬元素標準溶液檢量線之R2值與方法偵測極限值 56
表 10 尿液中砷物種標準溶液檢量線之R2值與方法偵測極限值 57
表 11 尿液標準參考品濃度值與分析量測值比較, μg/L 58
表 12 組織標準參考品濃度值與分析量測值比較, μg/g 59
表 13 尿液中砷物種標準參考品濃度值與分析量測值比較, μg/L 60
表 14 受試者個案基本資料 61
表 15 不同癌症病程個案尿液中之多種金屬元素濃度分布情形 62
表 16 不同性別、年齡層與腫瘤發生部位個案尿液中金屬元素濃度之分佈 63
表 17 不同癌症病程個案尿液中砷物種與一、二級甲基化指標之分布情形 64
表 18 不同性別、年齡層與腫瘤發生部位個案尿液中砷物種濃度與一、二級甲基化指標之分布 65
表 19 尿液中各種金屬元素與砷物種濃度之相關性 67
表 20 泌尿道癌症個案正常與腫瘤組織中金屬元素濃度分佈, 68
表 21 一般人尿液中金屬濃度分布之文獻探討, μg/L69

圖目錄
圖 1 HPLC-ICP-MS串聯構造圖(Agilent Technologies, 2009)72
圖 2 腎臟組織中金屬元素濃度之分布 73
附錄
附錄 1、收案問卷 74
附錄 2、檢量線 81
dc.language.isozh-TW
dc.title腎細胞癌及移行性上皮癌與腎臟皮質、腎盂、輸尿管中金屬元素關係之探討-前驅研究zh_TW
dc.titleInvestigation on the association of renal cell carcinoma and transitional cell carcinoma with metals levels in the renal cortex, pelvis, and ureter - A pilot study.en
dc.typeThesis
dc.date.schoolyear98-2
dc.description.degree碩士
dc.contributor.oralexamcommittee王榮德,王碩盟
dc.subject.keyword重金屬,砷物種,尿液,組織,腎臟癌,zh_TW
dc.subject.keywordHeavy metals,Arsenic speciation,Urine,Tissue,Kidney cancer,en
dc.relation.page84
dc.rights.note有償授權
dc.date.accepted2010-07-28
dc.contributor.author-college公共衛生學院zh_TW
dc.contributor.author-dept職業醫學與工業衛生研究所zh_TW
顯示於系所單位:職業醫學與工業衛生研究所

文件中的檔案:
檔案 大小格式 
ntu-99-1.pdf
  目前未授權公開取用
973.3 kBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved